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Background: We investigated 1) the frequency of hypertension in patients with type 2 diabetes graded by the
new classification of chronic kidney disease (CKD) reported by the Kidney Disease: Improving Global Outcomes
(KDIGO) and 2) the number of antihypertensive agents needed to achieve treatment goals using a prospective
observational study.
Methods: A population of 2018 patients with type 2 diabetes mellitus was recruited for the study. The CKD stage
was classified according to the eGFR and the urinary albumin excretion levels.
Results: Hypertension was found in 1420 (70%) of the patients, and the proportion of subjects showing a blood
pressure< 130/80 mmHg was 31% at the baseline. Although the mean blood pressure was approximately 130/
75 mmHg, the rate of patients with a blood pressure of< 130/80 mmHg became limited to 41-50% during the
observation period. The number of antihypertensive agents required for treatment was significantly higher at the
endpoint (2.0 ± 1.3) than at the baseline (1.6 ± 1.2). Furthermore, it increased with the progression of the CKD stage
at both the baseline and the endpoint of the observation. However, the frequency of subjects who did not achieve
the blood pressure target was found to increase in the group demonstrating the later stage of CKD.
Conclusions: Hypertension resistant to antihypertensive agents was common in the patients with type 2 diabetes
mellitus and increased with the progression of CKD. Although powerful combination therapy using
antihypertensive agents is considered necessary for the strict control of blood pressure, this became difficult in
individuals who were in advanced stages as graded based on the eGFR and the urinary albumin excretion levels.
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It is well-known that hypertension is common in the
patients with type 2 diabetes mellitus [1,2]. Hypertension
is a major risk factor for the onset and progression of
diabetic micro-a and macrovascular complications, as
well as hyperglycemia [3,4]. Furthermore, the risk for
cardiovascular events synergistically increases in the
patients with both diabetes mellitus and hypertension
[5]. The target blood pressure is recommended to be less
than 130/80 mmHg in order to prevent diabetic vascular
events [6,7]. Although it was reported that angiotensin-
converting enzyme inhibitors (ACEIs) and angiotensin II
receptor blockers (ARBs) have vascular protective
effects, especially in the patients with diabetic nephropa-
thy [8-13], it is often difficult to control blood pressure
using single agents, and combination therapy was
needed in many diabetic patients with hypertension [14].
The frequency of hypertension is elevated with the
progression of renal damage in both diabetic and non-
diabetic patients. In the present prospective observa-
tional study, we investigated 1) the frequency of hyper-
tension in the patients with type 2 diabetes as graded by
the new classification of chronic kidney disease (CKD)
reported by the Kidney Disease: Improving Global Out-
comes (KDIGO) [15] and 2) the number of antihyper-
tensive agents needed to achieve the treatment goals.
Methods
Ethics statement
This study was conducted according to the principles
expressed in the Declaration of Helsinki. The Ethics
Committees of Edogawa Hospital approved the protocol
of this study and waived the need for written informed
consent because the data were analyzed anonymously
for this observation study based on the data stored in
the hospital database.
Study population and methods
A population of 2018 patients diagnosed with type 2 dia-
betes mellitus who underwent consecutive evaluations,
including blood pressure, urinalysis and determination
of the serum creatinine levels in the Department of Dia-
betes, Metabolism and Kidney Disease of Edogawa Hos-
pital, Tokyo, Japan between April 2008 and March 2011
was recruited for the study. Antihypertensive agents
were essentially initiated when a systolic blood pressure
(SBP)≥ 130 mmHg and/or a diastolic blood pressure
(DBP) ≥ 80 mmHg persisted after the lifestyle modifica-
tion. The selection of antihypertensive agents was deter-
mined by each patient’s physician during the prospective
observation period.
The blood pressure was measured twice with the sub-
jects in the sitting position after a 5 minute rest. The
lower value of the two measurements was used for thestudy. Hypertension was defined as a SBP ≥ 140 mmHg
and/or a DBP ≥ 90 mmHg. The participants currently
using antihypertensive medications were also classified
as positive for hypertension. The target blood pressure
is less than 130/80 mmHg according to the JNC7 [6]
and the guidelines proposed by the European Society
of Hypertension and of the European Society of
Cardiology [8].
The patients were divided into four groups according to
their blood pressure status. Categories 1, 2, 3 and 4 were
defined to be the subjects showing 1) SBP< 130 mmHg
and DBP< 80 mmHg, 2) SBP< 130 mmHg and DBP≥
80 mmHg, 3) SBP≥ 130 mmHg and DBP< 80 mmHg,
and 4) SBP≥ 130 and DBP≥ 80 mmHg, respectively. The
doses and specific drug classes of antihypertensive agents
for blood pressure control were dependent on the
judgment of each patient’s physician.
The number of antihypertensive agents used was
expressed as the sum of antihypertensive agents such as
thiazide diuretics, loop diuretics, aldosterone antago-
nists, alpha blockers, beta blockers, calcium channel
blockers (CCBs), ACEIs, ARBs, renin inhibitors, and
centrally-acting adrenergic drugs being used.
The estimated glomerular filtration rate (eGFR) was
calculated using the formula reported by Matsuo et al.
[16]. This equation originated from the MDRD study
group [17] arranged for Japanese individuals, and it is
recommended by the Japanese Society of Nephrology:
eGFR (mL/min/1.73 m2) = 194×Scr-1.094×Age-0.287× 0.739
(if female).
The CKD stage was classified according to the eGFR
and the urinary albumin excretion (UAE). The GFR
stage was graded as: G1, eGFR ≥ 90 mL/min/1.73 m2;
G2, 90 mL/min/1.73 m2> eGFR ≥ 60 mL/min/1.73 m2;
G3a, 60 mL/min/1.73 m2> eGFR ≥ 45 mL/min/1.73 m2;
G3b, 45 mL/min/1.73 m2> eGFR ≥ 30 mL/min/1.73 m2;
G4, 30 mL/min/1.73 m2> eGFR ≥ 15 mL/min/1.73 m2;
and G5, 15 mL/min/1.73 m2> eGFR [15]. The UAE is
presented as the albumin-to-creatinine ratio (ACR;
mg/g creatinine). The albuminuria stage was graded
according to an analysis of a spot urine sample as: A1
(normoalbuminuria), ACR< 30 mg/g creatinine; A2
(microalbuminuria), 30 ≤ACR< 300 mg/g creatinine;
or A3 (macroalbuminuria), ACR ≥ 300 mg/g creatinine
(or dipstick urinalysis revealing 2+, 3+ or 4+).
The HbA1c levels were determined by a high per-
formance liquid chromatography method using an
automated HLC-723 G7 analyzer (Tosoh Corporation,
Tokyo, Japan) and calibrated by the Japan Diabetes So-
ciety (JDS) standard calibrators. The value for HbA1c
(%) was estimated as a National Glycohemoglobin
Standardization Program (NGSP) equivalent value (%)
calculated by the formula: HbA1c =HbA1c (JDS) + 0.4,
considering the relational expression of HbA1c (JDS)
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and the measurement methods and HbA1c (NGSP)
[18].
Statistical methods
All data are shown as the means ± SD. An analysis of
variance (ANOVA) and the χ2 test were used for
between-group comparisons of the continuous and
categorical variables, respectively. A paired-t test was
performed to determine the significance of the change
in the number of antihypertensive agents. Differences of
P< 0.05 (two-tailed) were considered to be statistically
significant. The statistical software package JMP, version
8.0 (SAS Institute, Cary, NC, USA), was used to perform
all of the analyses.
Results
Table 1 shows the baseline clinical characteristics and
the laboratory parameters of the patients. Hypertension




Age (years) 63 ± 12 2018 (100)
Men 62 2018 (100)
Duration of diabetes mellitus (years) 9.4 ± 9.8 1723 (85)
Current plus past smoking 59 1585 (79)
Drinkers # 42 1671 (83)
Treatment for diabetes mellitus 2018 (100)
Diet only/OHA/insulin/GLP-1 analogue 17/56/27/0
Body mass index (kg/m2) 24.9 ± 4.3 1995 (99)
Obesity ## 44 1995 (99)
Systolic blood pressure (mmHg) 139± 21 2018 (100)
Diastolic blood pressure (mmHg) 80 ± 14 2018 (100)
Hypertension 70 2018 (100)
Number of antihypertensive agents 1.6 ± 1.2 1420 (70)
Control of blood pressure 2018 (100)
Category 1 31 629
Category 2 4 90
Category 3 20 407
Category 4 44 892
HbA1c (%) 8.5 ± 2.2 1887 (94)
Glycoalbumin (%) 24.7 ± 8.4 206 (10)
Estimated GFR (mL/min/1.73 m2) 55 ± 20 2018 (100)
OHA: oral hypoglycemic agents, GFR: glomerular filtration rate.
# Drinkers were defined as those who consumed more than 20 g/day of
ethanol.
## Obesity was considered to be present in individuals with a body mass index
≥ 25 kg/m2.subjects showed a blood pressure< 130/80 mmHg. No
antihypertensive agent was administered to 259 patients
with hypertension. The number of antihypertensive
agents used was 1, 2, 3, 4, 5, 6 and 7 in 471, 403, 196,
63, 21, 6 and 1 patients, respectively. The mean number
of antihypertensive agents being used by the patients
with hypertension and diabetes was 1.6.
The distribution of the patients divided by their albu-
minuria stage and GFR stage is shown in Table 2. The
frequency of hypertension was significantly increased
with the progression of the albuminuria stage (P< 0.01)
and the GFR stage (P< 0.01) (Figure 1).
Figure 2-A shows the blood pressure during the
observation period in all subjects. Although the mean blood
pressure was improved (132/75 mmHg, 131/75 mmHg,
129/73 mmHg and 130/68 mmHg at 12, 24, 26 and
48 months, respectively), the rate of patients who were in
category 1 (SBP< 130 mmHg and DBP< 80 mmHg) was
limited to 41-50% of the patients (Figure 2-B). In the 1359
patients who were observed for more than 12 months, the
final blood pressure was 131±16/74±12 mmHg, and the
rate of patients in category 1 was 43%. The percentages of
individuals who did not achieve the target blood pressure
(Categories 2+3+4) were decreased at the endpoint of the
observation compared with the baseline (Figure 3). They
percentage increased in the subjects demonstrating later
stage of the albuminuria (P< 0.01) and the GFR (P< 0.01)
at the endpoint of the observation (Figure 3-B).
Table 2 shows a comparison of the number of antihy-
pertensive agents used in the patients with hypertension
and diabetes at the baseline (n= 1420) and at the end-
point of the observation for more than 12 months
(n= 990). The number of antihypertensive agents was
significantly higher at the endpoint than at the baseline.
Furthermore, it increased with the progression of CKD
stage at both the baseline and the endpoint of the
observation period.
CCBs, ACEIs, ARBs and thiazide diuretics were used by
52%, 15%, 55% and 13% of the patients at the baseline, and
by 64%, 23%, 65% and 7% at the endpoint of the observa-
tion period.
Discussion
In the present study, a much higher frequency of hyper-
tension was found in the patients with type 2 diabetes
mellitus. It could be argued that this is because our
study included a number of CKD patients, although our
results were consist with previous reports that showed
hypertension to be frequently complicated with diabetes
[1,2]. Our investigation is the first report showing that
the frequency of hypertension was elevated with the
progression of CKD, and that more drugs were needed
for the treatment of hypertension during the progression
of CKD. Furthermore, the percentage of patients who
Table 2 The number of antihypertensive agents used in the patients with hypertension and diabetes at the baseline
and at the endpoint of the observation
Albuminuria stage
A1 A2 A3 Average
GFR stage Baseline$ Endpoint$ Baseline$ Endpoint$ Baseline$ Endpoint$ Baseline$ Endpoint$
G1+G2 1.3 ± 1.0 1.7 ± 1.0 1.1 ± 1.0 1.7 ± 1.0 1.2 ± 0.8 2.0 ± 0.9$} 1.2 ± 1.0 1.7 ± 1.0
n (% of all) 261 (18.3) 182 (18.4) 127 (8.9) 79 (8.0) 58 (4.1) 37 (3.7) 446 (31.4) 298 (40)
G3a# 1.4 ± 1.0 1.7 ± 1.0 1.4 ± 1.1 1.8 ± 1.2 1.5 ± 0.9 2.3 ± 1.2 1.4 ± 1.0 1.8 ± 1.1
n (% of all) 269 (18.9) 217 (21.9) 140 (9.9) 82 (8.3) 86 (6.1) 68 (6.9) 495 (34.9) 367 (37.1)
G3b# 1.9 ± 1.1 2.1 ± 1.2 1.5 ± 1.3 2.0 ± 1.1 2.0 ± 1.3 2.6 ± 1.4 1.9 ± 1.3 2.3 ± 1.3*
n (% of all) 123 (8.7) 93 (9.4) 63 (4.4) 40 (4.0) 106 (7.5) 79 (8.0) 292 (20.6) 212 (21.4)
G4 +G5 3.0 ± 1.6 3.2 ± 1.8 2.4 ± 1.6 2.6 ± 1.2 2.5 ± 1.3 2.9 ± 1.4 2.5 ± 1.4 2.9 ± 1.4
n (% of all) 10 (1.0) 6 (0.9) 22 (1.5) 8 (0.8) 155 (10.9) 99 (10) 187 (13.2) 113 (11.4)
Average*# 1.5 ± 1.1 1.8 ± 1.1 1.4 ± 1.2 1.8 ± 1.1 2.0 ± 1.3 2.5 ± 1.4 1.6 ± 1.2 2.0 ± 1.3
n (% of all) 663 (46.7) 498 (50.3) 352 (24.8) 209 (21.1) 405 (28.5) 283 (28.6) 1420 (100) 990 (100)
* P< 0.01 among A1, A2 and A3 at baseline and # P< 0.01 among A1, A2 and A3 at endpoint.
$ P< 0.01 among G1 +G2, G2, G3 and G4 +G5.
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demonstrating the later stage of CKD, despite their
increased use of antihypertensive agents.
Bakris et al. reviewed the various clinical trials for ei-
ther diabetes or renal impairment. An average of 3.2 dif-
ferent antihypertensive medications was taken daily in
the UKPDS [3], ABCD [19], MDRD [20], HOT [21] and
AASK [22] trials, even though the average blood pres-
sure in these patients was slightly less than 140/
90 mmHg [14]. The mean blood pressure of our study
reached approximately 130/75 mmHg at the endpoint of
observation using fewer drugs. The differences were
considered to be caused by the use of more recent anti-
hypertensive agents, such as long-acting CCBs and
ARBs. Because the essential antihypertensive agents were
thiazide diuretics, beta blockers, CCBs and/or ACEIs in
these previous investigations, it is difficult to make a
simple comparison to the present study.Figure 1 The frequency of hypertension in the groups
subdivided by albuminuria (A1-A3) and GFR (G1+2, G3a, G3b
and G4+5) stages.The target value of blood pressure has continued to
decline after the JNC I [23] was published as the first
guideline for the treatment of hypertension in 1977. As
strict control is required, especially in diabetic patients,
we also tried to keep the blood pressure less than 130/
80 mmHg in the present study. However, our current
treatment protocol was considered to be insufficient for
blood pressure control in patients with type 2 diabetes,
even when a combination using two or more antihyper-
tensive drugs was administered (the subjects who met
the treatment goal comprised only ~50% of the popu-
lation at the endpoint). Furthermore, tight control be-
came more difficult as the CKD stage progressed.Figure 2 (A) The blood pressure and (B) status of blood
pressure control during the follow-up period. The data represent
the means ± SD.
Figure 3 The percentages of individuals who did not achieve the target blood pressure (Categories 2+3+4) among the patients with
different CKD stages at the baseline (A) and at the endpoint of observation (B) in the total of 1359 patients who were observed for
more than 12 months.
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to use various antihypertensive agents showing more
powerful effects such as can be achieved using long-
acting CCBs, ACEIs, ARBs and renin inhibitors. More
aggressive treatment strategies, including some com-
bination tablets, are therefore desirable in addition to
the lifestyle modifications, in order to increase the like-
lihood that the target blood pressure can be reached
and maintained.
Therapeutic resistance to antihypertensive agents in
the late stage of CKD with diabetes mellitus is consid-
ered to be caused some defective mechanisms of vascu-
lar homeostasis and impaired nitric oxide production
[24]. Vascular repair, according to a renal hemodynamic
study [25], and nitric oxide production from the renal
endothelial cells [26], have both been reported to be ad-
equately functional in patients with the early stage of
diabetic nephropathy. However, the number of antihy-
pertensive agents had been higher during the entire ob-
servation period, even in the early stage (G1 +G2 and
A1) of diabetic nephropathy, in the present study. This
is thought to be due to the insufficient number of anti-
hypertensive agents (1.3 ± 1.0) taken at the baseline by
the G1 +G2/A1 stage patients.
The present study has several important limitations.
First, the follow-up period was relatively short, and the
number of patients decreased to nearly one-half at
24 months and to one-fourth at 36 months. This might
have led us to incorrectly estimate the blood pressure
control and the number of antihypertensive agents
required for control. Second, we did not determine the
dose of antihypertensive agents required. The doses
administered were dependent on the judgment of each
patient’s physician, as was the decision to add another
antihypertensive agent or increase the dose of a drugthat was already being used. When the dose increases,
the enhanced antihypertensive therapy is not reflected in
the number of antihypertensive agents. Third, the blood
pressure measured at home was not evaluated in this
study. If self-monitoring of blood pressure shows good
control for hypertension, then physicians will not in-
crease the therapy, even if the office blood pressure does
not meet the target goal levels. This is considered to be
one of the reasons why more than half of the patients
remained within categories 2–4 in the present study.
Fourth, the lower value of two measurements of blood
pressure was used for this study, not the average value,
which is recommended by the National Institutes of
Health [6] and the Japanese Society of Hypertension
[27]. This might have led to the underestimation of the
blood pressure level observed in this investigation. Fifth,
the number of patients gradually decreased during the
observation period. It was possible that the omission of
individuals with higher blood pressure had thus caused
the improvement in the blood pressure that was seen
during the observation period.Conclusion
In conclusion, hypertension was common in patient with
type 2 diabetes mellitus and increased with the progres-
sion of CKD. Although powerful combination therapy
using antihypertensive agents is considered to be neces-
sary for the strict control of blood pressure, it becomes
more difficult for individuals in the progressive stages of
CKD as determined based on the albuminuria and GFR
levels.Competing interests
The author(s) declare that they have no competing interests.
Ito et al. BMC Nephrology 2012, 13:48 Page 6 of 6
http://www.biomedcentral.com/1471-2369/13/48Authors’ contributions
HI contributed to the conception and design of the study, research, analysis
and interpretation of data, and the drafting of the manuscript. MM, MA, KO,
SA, YT, MT, SA and ET contributed to the research and interpretation of the
data, and to the critical revision of the manuscript. All authors have given
their final approval of the submitted version of the manuscript. All authors
read and approved the final manuscript.Acknowledgements
The authors thank Ms. Tomoko Koyanagi of the secretarial section of
Edogawa Hospital for her valuable help in the data collection.
Author details
1Department of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital,
2-24-18, Higashi-Koiwa, Edogawa, Tokyo 133-0052, Japan. 2Pharmaceutical
Department, Edogawa Hospital, 2-24-18, Higashi-Koiwa, Edogawa, Tokyo
133-0052, Japan.
Received: 23 January 2012 Accepted: 27 June 2012
Published: 27 June 2012References
1. Kannel WB: Risk factors in hypertension. J Cardiovasc Pharmacol 1989, 13
(Suppl 1):S4–S10.
2. Iimura O: Insulin resistance and hypertension in Japanese. Hypertens Res
1996, 19(Suppl 1):S1–S8.
3. UK Prospective Diabetes Study Group: Tight blood pressure control and
risk of macrovascular and microvascular complications in type 2
diabetes: UKPDS 38. BMJ 1998, 317:703–713.
4. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of
intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577–1589.
5. American Diabetes Association: Role of cardiovascular risk factors in
prevention and treatment of macrovascular disease in diabetes. Diabetes
Care 1989, 12:573–579.
6. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones
DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, Joint National Committee
on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
National Heart, Lung, and Blood Institute; National High Blood Pressure
Education Program Coordinating Committee: Seventh report of the Joint
National Committee on Prevention, Detection, Evaluation, and Treatment
of High Blood Pressure. Hypertension 2003, 42:1206–1252.
7. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi
G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A,
Schmieder RE, Boudier HA, Zanchetti A, ESH-ESC Task Force on the
Management of Arterial Hypertension: Management of Arterial Hypertension
of the European Society of Hypertension; European Society of Cardiology.
2007 Guidelines for the Management of Arterial Hypertension: The Task
Force for the Management of Arterial Hypertension of the European
Society of Hypertension (ESH) and of the European Society of Cardiology
(ESC). J Hypertens 2007, 2007(25):1105–1187.
8. Heart Outcomes Prevention Evaluation Study Investigators: Effects of
ramipril on cardiovascular and microvascular outcomes in people with
diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy.
Lancet 2000, 55:253–259.
9. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, The Collaborative Study Group:
The effect of angiotensin-converting-enzyme inhibition on diabetic
nephropathy. N Engl J Med 1993, 329:1456–1462.
10. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH,
Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators:
Effects of losartan on renal and cardiovascular outcomes in patients
with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869.
11. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins
RC, Rohde R, Raz I, Collaborative Study Group: Renoprotective effect of the
angiotensin-receptor antagonist irbesartan in patients with nephropathy
due to type 2 diabetes. N Engl J Med 2001, 345:851–860.
12. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P,
Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study
Group: The effect of irbesartan on the development of diabetic
nephropathy in patients with type 2 diabetes. N Engl J Med 2001,
345:870–878.13. Viberti G, Wheeldon NM, MicroAlbuminuria Reduction With VALsartan
(MARVAL) Study Investigators: Microalbuminuria reduction with valsartan
in patients with type 2 diabetes mellitus: a blood pressure-independent
effect. Circulation 2002, 106:672–678.
14. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas
J, Hsueh W, Sowers J: Preserving renal function in adults with hypertension
and diabetes: a consensus approach. Am J Kidney Dis 2000, 36:646–661.
15. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K,
Gansevoort RT, Kasiske BL, Eckardt KU: The definition, classification, and
prognosis of chronic kidney disease: a KDIGO Controversies Conference
report. Kidney Int 2011, 80:17–28.
16. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino
Y, Yokoyama H, Hishida A, Collaborators developing the Japanese equation
for estimated GFR: Revised equations for estimated GFR from serum
creatinine in Japan. Am J Kidney Dis 2009, 53:982–992.
17. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic
kidney disease and decreased kidney function in the adult US
population: Third National Health and Nutrition Examination Survey. Am
J Kidney Dis 2003, 41:1–12.
18. Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, Ito C, Inagaki
N, Iwamoto Y, Kasuga M, Hanafusa T, Haneda M, The Committee of the
Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus:
Report of the Committee on the Classification and Diagnostic Criteria of
Diabetes Mellitus. J Diabetes Invest 2010, 1:213–228.
19. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW: The
effect of nisoldipine as compared with enalapril on cardiovascular
outcomes in patients with non-insulin-dependent diabetes and
hypertension. N Engl J Med 1998, 338:645–652.
20. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ,
Klahr S, Massry SG, Seifter JL: Blood pressure control, proteinuria, and the
progression of renal disease. The Modification of Diet in Renal Disease
Study. Ann Intern Med 1995, 123:754–762.
21. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard
J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure
lowering and low-dose aspirin in patients with hypertension: principal
results of the Hypertension Optimal Treatment (HOT) randomized trial.
HOT Study Group. Lancet 1998, 351:1755–1762.
22. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D,
Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J,
Phillips RA, Toto RD, Middleton JP, Rostand SG, African American Study of
Kidney Disease and Hypertension Study Group: Effect of blood pressure
lowering and antihypertensive drug class on progression of hypertensive
kidney disease: results from the AASK trial. JAMA 2002, 288:2421–2431.
23. Joint National Committee: Report of the Joint National Committee on
Detection, Evaluation, and Treatment of High Blood Pressure. A
cooperative study. JAMA 1977, 237:255–261.
24. Futrakul N, Futrakul P: Vascular homeostasis and angiogenesis determine
therapeutic effectiveness in type 2 diabetes. Int J Vasc Med 2011, 2011:971524.
25. Futrakul N, Kulaputana O, Futrakul P, Chavanakul A, Deekajorndech T:
Enhanced peritubular capillary flow and renal function can be
accomplished in normoalbuminuric type 2 diabetic nephropathy. Ren
Fail 2011, 33:312–315.
26. Ritt M, Ott C, Raff U, Schneider MP, Schuster I, Hilgers KF, Schlaich MP,
Schmieder RE: Renal vascular endothelial function in hypertensive
patients with type 2 diabetes mellitus. Am J Kidney Dis 2009,
53:281–289.
27. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y,
Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim-Mitsuyama S, Kimura G,
Matsubara H, Matsuura H, Naruse M, Saito I, Shimada K, Shimamoto K,
Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S,
Ueshima H, Umemura S, Ishimitsu T, Rakugi H, Japanese Society of
Hypertension Committee: The Japanese Society of Hypertension
Guidelines for the Management of Hypertension (JSH 2009). Hypertens
Res 2009, 32:3–107.
doi:10.1186/1471-2369-13-48
Cite this article as: Ito et al.: Hypertension resistant to antihypertensive
agents commonly occurs with the progression of diabetic nephropathy
in Japanese patients with type 2 diabetes mellitus: a prospective
observational study BMC Nephrology 2012 13:48.
